PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,677,447 | trikoramid b bioactiv cyanobactin marin cyanobacterium symploca hydnoid three new cyanobactin trikoramid b isol marin cyanobacterium symploca hydnoid follow preliminari bioassay guid isol two activ polar fraction base brine shrimp toxic assay new cyanobactin new analogu previous report cytotox trikoramid differ main c prenyl cyclotryptophan unit planar structur elucid nmr spectral data combin hrmsms data marfey method noesi nmr spectroscop ecd spectra analys use determin absolut stereochemistri trikoramid b trikoramid b exhibit cytotox molt acut lymphoblast leukemia cell line ic valu respect compound also evalu quorum sens inhibitori assay base pseudomona aeruginosa pao lasb gfp rhla gfp bioreport strain although trikoramid b exhibit weak quorum sens inhibitori activ br contain trikoramid exhibit moder signific dose depend quorum sens inhibitori activ pao lasb gpf rhla gfp bioreport strain ic valu respect | D000458 | T007 |
34,677,445 | marin oligocarrageenan inhibit migratori invas abil mda mb human breast cancer cell action heparanas metabol mmp mmp axi sugar base molecul heparin natur heparan sulfat polysaccharid develop wide studi control heparanas hpse enzymat activ key player extracellular matrix remodel cancer pathogenesi howev non enzymat function hpse also describ tumour mechan given versatil properti hypothes sugar base inhibitor may interfer enzymat also non enzymat hpse activ work assess effect origin marin carrageenan deriv oligosaccharid co previous describ along nativ counterpart heparin cell viabil prolifer migrat invas mda mb breast cancer cell also sh mda mb cell express hpse select downregul observ cytotox anti prolif effect compound surpris co effici reduc cell migrat invas compar heparin hpse depend manner provid evid co tight control hpsemmp mmp axi lead reduc mmp activ altogeth studi highlight co potent hpse modul capabl reduc enzymat activ hpse also function control hpse level | D000461 | T002 |
34,677,444 | fucosterol marin macroalga bioactiv safeti toxic organ fucosterol ethyliden cholesterol bioactiv compound belong sterol group isol marin alga fucosterol marin alga exhibit various biolog activ includ anti osteoarthrit anticanc anti inflammatori anti photoag immunomodulatori hepatoprotect anti neurolog antioxid algicid anti obes antimicrobi numer studi fucosterol main focus quantif character chemic structur bioactiv health benefit fucosterol publish howev comprehens review safeti toxic level fucosterol marin alga review aim discuss bioactiv safeti toxic fucosterol comprehens import applic develop fucosterol bioactiv compound nutraceut pharmaceut industri use four onlin databas search literatur fucosterol publish identifi screen select analyz literatur use prefer report item systemat review meta analys method identifi studi review despit potenti applic fucosterol identifi need fill certain relat research gap fucosterol exhibit low toxic anim cell line human cell line anim howev studi safeti toxic fucosterol clinic stage requir fucosterol develop industri lack | D000975;D058086 | T044;T121;T123;T039;T204 |
34,677,443 | sp crus glycin rich region contribut larg antivir activ whole protein molecul interact vp wssv structur protein crustin cystein rich cation antimicrobi peptid divers biolog function includ antimicrobi proteinas inhibitori activ crustacean although crustin report respond white spot syndrom virus wssv infect detail antivir mechan crustin remain larg unknown previous research shown sp crus mud crab scylla paramamosain type ii crustin contain glycin rich region grr cystein rich region crr present studi found spcrus upregul gill wssv challeng knockdown spcrus inject doubl strand rna dsspcrus result remark increas virus copi mud crab infect wssv result suggest spcrus play critic role antivir immun mud crab gst pull assay show recombin sp crus interact specif wssv structur protein vp result confirm co immunoprecipit assay drosophila cell signatur sequenc type ii crustin sp crus grr glycin rich cation polypeptid amphipath properti studi demonstr grr crr sp crus exhibit bind activ vp former display potent bind abil latter interest pre incub wssv particl recombin sp crus r sp crus rgrr rcrr inhibit virus prolifer vivo moreov r sp crus rgrr possess similar antivir abil much stronger rcrr find indic sp crus grr contribut larg antivir abil sp crus stronger antivir abil grr might result stronger bind activ viral structur protein overal studi provid new insight antivir mechan sp crus develop new antivir drug | D003445 | T204 |
34,677,442 | efficaci chondroprotect food supplement base collagen hydrolys compound isol marin organ osteoarthr belong common joint diseas human anim show increas incid older patient bioactiv collagen hydrolys sulfat glucosamin special fatti acid enrich dog food test dog patient studi dog potenti therapeut treatment option earli osteoarthr biophys biochem cell biolog molecular model method support well defin substanc may act effect nutraceut import appli collagen hydrolys well sulfat glucosamin residu marin organ strong support anim model molecular model intermolecular interact molecular model predict interact dynam evalu receptor protein mmp adamt protein play promin role mainten cartilag health well innat adapt immun nutraceut data generat veterinari clinic studi focus mobil agil specif key clinic paramet mmp timp obtain blood probe german shepherd dog earli osteoarthr symptom fed collagen hydrolys collagen hydrolys chondroprotect food supplement examin high resolut nmr experi molecular model simul use character interact potenc collagen fragment glucosamin protein receptor structur potenti benefici effect collagen hydrolys sulfat glycan ie sulfat glucosamin crab mussel lipid especi eicosapentaeno acid extract fish oil biochem physiolog process discuss context human veterinari medicin | D019587 | T168;T061 |
34,677,441 | structur divers polycycl salicylaldehyd deriv enantiom marin deriv fungus eurotium sp scsio f enlarg chemic divers eurotium sp scsio f talent marin deriv fungus investig chemic constitu larg scale ferment modifi cultur four pair new salicylaldehyd deriv enantiom euroticin f well known one eurotirumin isol character compound featur unpreced construct tetracycl structur repres two new type scaffold structur establish comprehens spectroscop analys x ray diffract c nmr electron circular dichroism calcul select compound show signific inhibitori activ glucosidas moder cytotox activ sf mcf hepg cell line | D055325 | T004 |
34,677,440 | cartilag acid protein novel therapeut factor improv skin damag repair fish skin gain attent due efficaci human wound treatment product identifi factor promot enhanc action skin fibroblast central role maintain skin integr secret extra cellular matrix ecm protein growth factor cytokin rapid repair lesion prevent damag infect effect scratch repair ubiquit poor character ecm protein cartilag acid protein crtac piscin human sourc compar use zebrafish sjd primari fibroblast cell line classic vitro cell scratch assay immunofluoresc biosensor gene express analysi use result demonstr duplic sea bass crtaca crtacb protein human crtac promot sjd primari fibroblast migrat classic scratch assay electr cell imped sens assay immunofluoresc analysi reveal crtac enhanc cell migrat like caus actin driven cytoskelet chang cellular transcript respons affect earli stage h scratch repair summari result suggest crtac may import factor fish skin promot damag repair | D015027 | T013 |
34,677,439 | combin anticanc effect sulfat laminaran brown alga alaria angusta polyhydroxysteroid glycosid starfish protoreast lincki colorect carcinoma hct cell line colorect cancer one frequent type malign world search new approach increas efficaci cancer therapi relev work aim studi individu combin anticanc effect molecular mechan action sulfat laminaran aal brown alga alaria angusta protolinckiosid pl b pl linckosid l l starfish protoreast nbsp lincki use cell cultur model dimethylthiazol yl carboxymethoxyphenyl sulfophenyl h tetrazolium mts soft agar spheroid invas western blot assay perform determin effect mechan action investig compound combin prolifer coloni format invas hct spheroid aal pl pl l individu inhibit viabil coloni growth invas hct spheroid variabl degre greater activ linckosid l aal combin l exert synerg combin anticanc effect inactiv protein kinas b akt kinas consequ induct apoptosi via regul proapoptoticantiapoptot protein balanc obtain data efficaci combin anticanc effect laminaran deriv brown alga polyhydroxysteroid glycosid starfish open prospect develop new therapeut approach colorect cancer treatment | D000459;D013215 | T204 |
34,677,438 | protect effect ulva lactuca polysaccharid extract oxid stress kidney injuri induc galactos mice reactiv oxygen speci ros key factor caus mani diseas human bodi polysaccharid seawe shown signific antioxid activ vivo vitro amelior effect ulva lactuca polysaccharid extract upe renal injuri induc oxid stress analyz shown hematoxylin eosin stain result upe signific improv kidney injuri induc galactos gal addit protect mechan upe kidney explor result show upe could decreas level serum creatinin scr blood urea nitrogen bun serum cystatin c cys c lipid peroxid protein carbonyl dna oxid damag ohdg improv kidney glutathion content moreov upe signific increas activ superoxid dismutas glutathion peroxidas total antioxid activ mice upe also decreas level inflammatori cytokin tnf il investig express apoptot protein caspas show upe decreas express apoptot protein caspas result indic upe potenti therapeut effect renal injuri caus oxid stress provid new theoret basi treatment oxid damag diseas futur | D044445 | T002 |
34,677,437 | purif identif novel xanthin oxidas inhibitori peptid deriv round scad decapterus maruadsi protein hydrolys object present studi investig xanthin oxidas xo inhibitori effect peptid purifi identifi round scad decapterus maruadsi hydrolys rshs studi rshs obtain use three proteas neutras protamex alcalas among rshs h hydrolysi neutras display strongest xo inhibitori activ abund small peptid da four novel peptid purifi immobil metal affin chromatographi identifi nano high perform liquid chromatographi massmass spectrometri amino acid sequenc kgfp da fpsv da fpfp da wpdgr da respect peptid synthes evalu xo inhibitori activ result indic peptid fpsv mm fpfp mm exhibit higher xo inhibitori activ respect fluoresc spectra assay demonstr fluoresc quench mechan xo inhibitor fpsv fpfp static quench procedur studi inhibit kinet suggest inhibit fpsv fpfp revers type inhibit mix one molecular dock reveal import stack phe residu contain peptid phe contain xo xo inhibitori activ peptid | D005399 | T013 |
34,677,436 | cyclopeptid deriv spong deriv fungus acremonium persicinum f cyclopeptid usual play pivot role either viabil virul fungi two type cyclopeptid six new hydroxam siderophor cyclohexapeptid includ acremonpeptid e f complex aluminum ferric ion one new cyclic pentapeptolid aselacin togeth known compound aselacin c isol character spong deriv fungus acremonium persicinum f addit two new siderophor analogu chelat gallium ion ga ga iii acremonpeptid e ga iii acremonpeptid f use isol acremonpeptid e f prepar planar structur elucid hresim nmr absolut configur amino acid determin mean advanc marfey method x ray singl crystal diffract analysi x ray fluoresc xrf spectromet perform disclos element compound indic exist aluminum al al iii acremonpeptid e ga iii acremonpeptid e al iii acremonpeptid f ga iii acremonpeptid f display high vitro anti fungal activ compar amphotericin b aspergillus fumigatus aspergillus niger | D000164;D011161 | T004;T204 |
34,677,434 | dual target ptpb aldos reductas marin drug phosphoeleganin promis strategi treatment type diabet depth studi inhibitori mechan protein tyrosin phosphatas b ptpb aldos reductas ar enzym includ analysi insulin signal pathway phosphoeleganin marin deriv phosphoryl polyketid achiev phosphoeleganin demonstr inhibit enzym act respect pure non competit inhibitor ptpb mix type inhibitor ar addit silico dock analys evalu interact mode phosphoeleganin enzym perform interest studi show phosphoeleganin first exampl dual inhibitor polyketid extract marin invertebr could use versatil scaffold structur synthesi new design multipl ligand | D014561 | T008;T204 |
34,677,432 | oncolyt vaccinia virus harbor aphrocallist vastus lectin inhibit growth cervic cancer cell hela aphrocallist vastus lectin avl c type marin lectin produc spong previous studi demonstr gene encod avl enhanc cytotox effect oncolyt vaccinia virus oncovv varieti cancer cell studi inhibitori effect oncovv avl hela cervic cancer cell cell line spheroid abil explor result show oncovv avl could inhibit hela cell growth vivo vitro investig reveal avl increas virus replic promot express oasl protein stimul activ raf hela cell studi may provid insight novel way util lection avl | D011161 | T204 |
34,677,429 | anti inflammatori anticanc effect microalg carotenoid acut inflamm key compon immun system respons pathogen toxic agent tissu injuri involv stimul defens mechan aim remov pathogen factor restor tissu homeostasi howev uncontrol acut inflammatori respons may lead chronic inflamm involv develop mani diseas includ cancer nowaday need find new potenti therapeut compound rais worldwid scientif interest studi marin environ specif microalga consid rich sourc bioactiv molecul carotenoid natur isoprenoid pigment import benefici effect health due biolog activ carotenoid essenti nutrient mammal unabl synthes instead dietari intak compound requir carotenoid classifi caroten hydrocarbon carotenoid caroten xanthophyl oxygen deriv includ zeaxanthin astaxanthin fucoxanthin lutein cryptoxanthin canthaxanthin review summar present date knowledg anti inflammatori anticanc activ microalg carotenoid vitro vivo well latest status human studi potenti use prevent treatment inflammatori diseas cancer | D058086 | T204 |
34,677,428 | anti inflammatori azaphilon edibl alga deriv fungus penicillium sclerotiorum discov new medic entiti edibl marin alga continu natur product investig focus endophyt marin macroalga grateloupia sp two new azaphilon epi hypocrellon epi eupenicilazaphilon c togeth five known azaphilon hypocrellon eupenicilazaphilon c e e dimethylhepta dien yl dihydroxi methylbenzaldehyd sclerotiorin isochromophilon iv isol alga deriv fungus penicillium sclerotiorum structur isol azaphilon elucid spectrometr identif especi hresim cd nmr data analys concern bioactiv cytotox anti inflammatori anti fibrosi activ isol evalu result compound show select toxic toward neuroblastoma cell line sh syy among seven cancer one fibroblast cell line compound inhibit tnf induc nfb phosphoryl chang nfb activ compound respect promot inhibit smad mediat transcript activ stimul tgf | D058086;D010407 | T004;T204 |
34,677,427 | anti mycoplasma activ bacilotetrin c e cyclic lipodepsipeptid marin deriv bacillus subtili structur revis bacilotetrin b mycoplasma hyorhini common caus polyseros arthriti swine common contamin cell cultur laboratori continu research divers bioactiv compound bacillus subtili ggc discov uncommon cyclic lipotetrapeptid show inhibitori activ hyorhini similar structur previous report bacilotetrin b bacilotetrin c e new cyclic lipodepsipeptid isol etoac extract obtain ferment marin deriv bacillus subtili isol marin spong sampl collect gageo reef republ korea structur consist three leucin residu one glutam acid hydroxi fatti acid elucid detail analysi nmr hr esim data absolut configur amino acid hydroxi fatti acid establish advanc marfey method mosher method respect local l amino acid within compound determin retent time comparison purchas dipeptid standard partial hydrolys product use lc ms compound exhibit anti mycoplasma activ mic valu gml twofold stronger posit control biomycox detail analysi comparison spectroscop data bacilotetrin b led us revis structur | D001412 | T007 |
34,677,361 | review capillari pressur control valv microfluid microfluid offer microenviron reagent deliveri handl mix reaction detect often demand affili equip liquid control function help tool capillari pressur control valv cpcv becom popular avoid use affili equip liquid handl control manner use bubbl pressur effect paper analyz categor cpcvs via three determin paramet surfac tension contact angl microchannel shape final applic scenario impact cpcv list includ cpvc simplifi autom microfluid network work drive mode make extens use microfluid open channel sampl deliveri control manner author hope review help develop use cpcv microfluid field research industri | D044085 | T090 |
34,677,360 | chronic studi brainwav authent real life set lstm base bag approach advent digit age concern secur author access sensit data increas besid tradit authent method interest biometr trait fingerprint iri facial characterist recent brainwav primarili base electroencephalographi eeg current work eeg base authent focus acut record laboratori set use high end equip typic equip channel oper high sampl rate work valid feasibl eeg base authent real world laboratori set use commerci dri electrod eeg headset chronic record popul healthi peopl use lstm base network bootstrap aggreg bag decod record respons multitask scheme consist perform imagin motor task show improv perform standard lstm approach achiev authent accuraci fals accept rate far fals reject rate frr perform motor task imagin motor task combin task respect recommend propos method time data limit scenario | D001699;D058256 | T062;T042 |
34,677,359 | biometr identif taxodium spp hybrid progeni electrochem fingerprint use electrochem fingerprint plant identif emerg applic biosensor work taxodium ascenden distichum mucronatum hybrid progeni collect purpos first attempt use electrochem fingerprint identif plant hybrid progeni electrochem fingerprint leav taxodium spp record two condit result show electrochem fingerprint speci progeni possess suitabl reproduc electrochem fingerprint repres electrochem behavior electrochem activ substanc leaf tissu specif condit sinc speci progeni close relat challeng identifi direct use particular electrochem fingerprint therefor electrochem fingerprint measur differ condit use perform pattern recognit identifi differ speci progeni locat featur differ pattern map also perform phylogenet studi data electrochem fingerprint result prove electrochem classif result relationship close relat | D056667;D015374;D032489 | T066;T002;T059;T075 |
34,677,358 | enhanc plasmon biosensor util pair antibodi label free fe nanoparticl high sensit select detect parkinson synuclein serum parkinson diseas pd acut progress neurodegen disord diagnosi diseas earliest stage paramount import improv life expect patient synuclein syn potenti biomark earli diagnosi pd great need develop biosens platform precis detect syn human bodi fluid herein develop surfac plasmon reson spr biosensor base label free iron oxid nanoparticl fe nps pair antibodi high sensit select detect syn serum sampl sensit spr platform enhanc signific direct deposit fe nps au surfac high densiti increas decay length evanesc field au film moreov util rabbit type monoclon antibodi syn rmab immobil au film allow spr platform high affin select bind perform compar mous type monoclon antibodi common bioreceptor captur syn molecul result current platform detect limit nbsp fgml fold lower commerci elisa improv sensor chip also easili regener repeat syn measur sensit furthermor spr sensor appli direct analysi syn serum sampl use format pair syn rmab spr sensor provid recoveri rate rang detect syn dilut serum sampl precis work demonstr high sensit select quantif approach detect syn human biofluid pave way futur develop earli diagnosi pd | D015374;D053758;D010300 | T047;T059;T073;T075 |
34,677,357 | dielectrophoret electr imped differenti cancer cell base biophys phenotyp report studi detect electr character cancer cell line primari tumor cell dielectrophoresi dep electr imped spectroscopi ei joint employ enabl rapid label free differenti various cancer cell normal one primari tumor cell collect two colorect cancer patient cancer cell line sw jurkat thp healthi peripher blood mononuclear cell pbmcs trap first level interdigit microelectrod help dielectrophoresi correl cell dielectr characterist obtain via electr imped spectroscopi ei allow evid differenti various type cell differenti assign dielectr phenotyp base crossov frequenc final randl equival circuit model employ highlight differ regard seri group charg transport resist constant phase element cancer normal cell | D058266;D007963 | T025;T059 |
34,677,356 | self referenc refract index biosens graphen fano reson mode hybrid structur compos period monolay graphen nanoribbon dielectr multilay structur design generat fano reson fr strong interact surfac plasmon reson graphen dielectr waveguid mode result fr finit element method util investig behavior fr match well theoret calcul use rigor coupl wave theori result demonstr profil fr passiv tune period graphen nanoribbon activ tune fermi level graphen decoupl natur fr give potenti applic self calibr refract index biosensor sensit reach high mriu thus work provid new idea excel self referenc refract index biosensor | D015374;D006108;D037742 | T109;T073;T104;T196;T075;T059 |
34,677,355 | investig regul neural differenti injuri pc cell use microstructur topograph cue studi design manufactur seri differ microstructur topograph cue induc neuron differenti cell vitro differ topographi size structur complex cultur pc cell microstructur cue induc neural differenti use nerv growth factor ngf pheochromocytoma cell line pc valid neuron cell model wide use studi neuron differenti relev marker neural differenti cytoskelet f actin character cellular immunofluoresc detect axon length analysi show differenti pc cell signific differ differ isotrop anisotrop topograph cue express differ growth cone marker growth associ protein gap sympathet nerv marker tyrosin hydroxylas th gene also studi differ topograph cue result reveal physic environ import influenc differenti neuron cell constraint could use guid axon extens addit neurotoxin hydroxydopamin ohda use detect differenti injuri pc cell differ topograph cue final discuss feasibl combin topograph cue microfluid chip neural differenti research | D002454;D003463;D009474 | T043;T025;T078 |
34,677,354 | electr imped upper limb enabl robust wearabl ident recognit variat finger placement environment factor biometr authent technolog commerci various field main reli acquir imag structur inform fingerprint iris face howev bio recognit techniqu use exist physic featur alway risk templat forgeri threat fake fingerprint due risk theft duplic studi recent attempt use intern structur biolog characterist human bodi includ previous work ratiometr biolog imped featur howev one may still question accuraci real life use due artifact sens posit variabl electrod skin interfac nois moreov sinc finger possess sever thermoregulatori vasomot larg variabl tissu properti core bodi necessari mitig harsh chang occur peripher extrem human bodi address challeng propos biometr authent method robust featur extract upper limb imped acquir base portabl wearabl devic work show upper limb imped featur obtain wearabl devic robust undesir factor finger placement deviat day day physiolog chang along ratiometr imped featur overal upper limb imped base analysi dataset measur subject lower classif error rate factor factor combin ratiometr featur | D000076251 | T073 |
34,677,353 | comput simul surfac charg nanobiosensor intern signal integr ioniz state molecular analyt locat solid surfac requir profound investig better understand applic basic scienc general design nanobiosensor particular ioniz state induc interact molecul analyz substanc target surfac comput simul use comsol multiphys softwar show effect surfac charg densiti distribut output generat dynam pin diod gate control devic built potenti barrier uniqu intern integr output signal generat identifi interact show possibl new design implement nanobiosensor base dynam pin diod mode surfac charg control | D015374 | T059;T075 |
34,677,352 | malign biosensor focus oral cancer detect salivari biomark oral cancer among deadliest type malign due late stage usual diagnos leav patient averag five year surviv rate less boom field biosens point care diagnost regard play major role earli detect oral cancer saliva gain interest altern biofluid non invas diagnost mani salivari biomark oral cancer propos find promis applic salivaom tool routin practic studi larger cohort still need clinic valid review aim summar recent develop field biosens relat detect salivari biomark common associ oral cancer introduct oral cancer diagnosi prognosi treatment given defin clinic problem clear saliva altern biofluid present along advantag disadvantag collect procedur final brief paragraph promis salivari biomark introduc sens technolog common exploit detect oral cancer marker saliva henc review provid comprehens overview clinic technolog advantag challeng associ oral cancer detect salivari biomark | D015374;D009062 | T191;T059;T075 |
34,677,351 | topograph vacuum seal print multiplanar microfluid structur demonstr novel way creat three dimension microfluid channel capabl follow complex topographi end substrat open channel differ geometri print open channel consecut close thermoplast use low resolut vacuum form approach process allow seal channel locat surfac complex multiplanar topographi thermoplast align surfac shape macrostructur substrat microchannel remain most free thermoplast small channel size resist thermoplast inflow new process analyz capabl consist close differ substrat geometri show reliabl seal angl furthermor thermoplast intrus channel differ width quantifi show linear effect channel width percentag thermoplast intrus rang larg channel mm width channel channel width challeng seal substrat valley creat two larg protrus adjac investig correl protrus distanc height shown last present three applic exampl serpentin mixer channel spun around cuboid increas usabl surfac area cuvett inspir flow cell mxp biosensor base molecular imprint polym fit insid standard uvvi spectrophotomet adapt system manufactur one side inject mold self seal usag exampl demonstr novel technolog use easili adapt microfluid circuit applic biosensor platform | D044085;D054843 | T061;T074;T090 |
34,677,350 | liquid biopsi base biosensor mrd detect treatment monitor non small cell lung cancer nsclc global non small cell lung cancer nsclc lead caus cancer death despit advanc chemotherapi target therapi year surviv rate remain past forti year minim residu diseas mrd describ exist either isol tumour cell circul tumour cell biolog liquid patient remov primari tumour without clinic sign cancer recent liquid biopsi promis non invas method diseas monitor treatment guidelin mrd marker liquid biopsi could use detect assess earlier stage nsclc post treatment mrd resist target therapi immun checkpoint inhibitor ici tumour mutat burden mrd surveil propos potenti marker lung cancer relaps princip biosensor provid quantit analysi various materi convert biolog function quantifi signal biosensor usual oper detect antibodi enzym dna rna extracellular vesicl ev whole cell present categori biosensor base signal transduct method identifi biosensor base biomark liquid biopsi specimen monitor lung cancer treatment | D015374;D002289;D008175 | T191;T059;T075 |
34,677,349 | biomechan physiolog evalu multi joint exoskeleton activ passiv assist walk improv walk effici ensur wearabl import issu lower limb exoskeleton activ devic provid greater forc passiv devic advantag weight present multi joint exoskeleton activ hip extens assist passiv ankl plantarflexion assist work admitt control base feedforward model propos track desir activ forc hip extens underfoot clutch mechan adapt realiz passiv ankl plantarflexion assist assess efficaci multi joint exoskeleton assist walk conduct comprehens experi evalu forc track perform lower limb muscl activ metabol cost result demonstr averag track error peak hip extens assist forc three subject less ii reduct normal root mean squar emg later soleus medial soleus gluteus maximus eight subject achiev respect iii averag metabol cost six subject reduc exoskeleton eo condit compar condit walk exoskeleton ne work prove concept multi joint exoskeleton activ passiv assist improv walk effici | D000067190;D016138 | T074;T169;T056 |
34,677,348 | site detect carcinoembryon antigen human serum real time connect employ sustain materi empow point care diagnost capabl send clinic relev data health care provid even low resourc set studi develop advantag kit site detect carcinoembryon antigen cea human serum cea sens perform use cellulos base later flow strip colorimetr signal read process measur use smartphon base system correspond immunoreact report polydopamin modifi gold nanoparticl order boost signal intens improv surfac block signal nois relationship therebi enhanc detect sensit compar bare gold nanoparticl fold term visual limit detect later flow strip show linear rang ngml visual limit detect ngml assay time min twenti six clinic sampl also test use propos kit compar gold standard immunoassay enzym link immunosorb assay demonstr excel correl r approach potenti util monitor cancer treatment particular locat far central laboratori facil | D015374 | T059;T075 |
34,677,347 | oxygen satur behavior puls oximetri femal athlet break myth myth surround women particip sport reflect respiratori physiolog studi aim demonstr continu monitor blood oxygen satur maxim exercis test femal athlet high correl determin second ventilatori threshold vt anaerob threshold ant measur perform use puls oximet maximum effort test treadmil popul healthi femal athlet common behavior oxygen satur evolut increment exercis test character decreas satur aerob threshold aet follow second signific drop observ decreas peripher oxygen satur physic exert relat athlet physic fit condit howev drop limit factor women physic perform found statist signific correl maximum oxygen uptak appear ventilatori threshold vt vt desatur time total test time desatur time vt observ relationship desatur time vt appear inde linear regress model desatur time vt appear predict valu sampl besid suggest puls oximetri simpl fair accur non invas techniqu studi physic condit athlet perform physic exert | D010092;D010101;D000089382 | T059;T060;T201 |
34,677,346 | theoret model high sensit near infrar biosensor base bloch surfac wave dirac semimet work present theoret model near infrar sensit refract index biosensor base truncat photon crystal pc structur dirac semimet high sensit near infrar biosensor origin sharp reflect peak caus excit bloch surfac wave bsw interfac dirac semimet pc sensit biosensor model sensit fermi energi dirac semimet thick truncat layer refract index sens medium optim structur paramet maximum refract index sensit biosensor model surpass riu achiev certain competit compar convent surfac plasmon reson spr bsw sensor consid bulk materi easier handl two dimension materi manufactur facil judg dirac semimet relat devic provid strong competitor altern graphen base devic | D015374;D006108 | T109;T059;T196;T075 |
34,677,345 | brain comput interfac use function near infrar spectroscopi fnir function near infrar spectroscopi fnir wearabl optic spectroscopi system origin develop continu non invas monitor brain function measur blood oxygen concentr recent advanc brain comput interfac allow us control neuron function brain combin fnir regul cognit function review manuscript provid inform regard current advanc fnir provid advantag develop brain comput interfac enabl neuron function also briefli discuss use technolog applic | D001921;D019265 | T023;T059 |
34,677,344 | microfluid lab chip base uhf dielectrophoresi stem phenotyp character discrimin among glioblastoma cell glioblastoma gbm one aggress solid tumor particular due presenc cancer stem cell cscs nowaday character cell type effici fast low cost method remain issu henc develop microfluid lab chip base dielectrophoresi dep singl cell electro manipul measur two crossov frequenc fx low frequenc rang khz fx ultra high frequenc rang uhf mhz first vitro condit investig u mg cell line cultur differ condit order induc undifferenti phenotyp ex vivo gbm cell patient primari cell cultur pass develop microfluid system character order reflect clinic condit articl demonstr usual exploit low frequenc rang dep allow discrimin undifferenti gbm cell differenti one howev present studi highlight use uhf dep relev discrimin paramet propos microfluid lab chip abl follow kinet u mg phenotyp transform csc enrich medium cancer stem cell phenotyp acquir | D004586;D005909;D056656 | T191;T059;T075 |
34,677,343 | noncontact optic measur aqueous humor glucos level correl serum glucos level rabbit noninvas measur serum glucos level investig monitor blood sugar control diabet studi aim develop novel noncontact glucomet ncgm util optic approach measur intraocular aqueous humor glucos level anterior chamber rabbit eye ncgm consist hybrid optic system simultan measur near infrar absorpt polar rotatori distribut glucos molecul aqueous humor vitro optic measur demonstr ncgm measur high precis repeat differ glucos level includ mgdl mgdl mgdl mgdl mgdl mgdl mgdl rabbit experi found high correl aqueous glucos level serum glucos level mean differ mgdl accord test result vivo ncgm measur aqueous humor glucos level also display high correl serum glucos level mean differ mgdl conclus aqueous humor glucos level accur measur use ncgm result correl serum glucos level | D001082;D003920 | T039;T047;T031 |
34,677,341 | applic microfluid liquid crystal base biosensor liquid crystal lcs stimuli respons configur transit optic anisotrop properti attract enorm interest develop simpl label free biosensor combin microfluid lcs offer great advantag tradit lc base biosensor includ small sampl consumpt fast analysi low cost moreov microfluid techniqu provid promis tool fabric uniform reproduc lc base sens platform review emphas recent develop microfluid fabric integr lc base biosensor includ lc planar sens platform lc droplet fabric integr lc base planar platform microfluid biosens applic first introduc generat entrap monodispers lc droplet differ microfluid structur well applic detect chemic biolog speci summar final challeng futur perspect develop lc base microfluid biosensor propos review promot understand microfluid techniqu lc base biosensor facilit develop lc base microfluid biosens devic high perform | D015374;D050866;D044085 | T073;T104;T075;T059;T090 |
34,677,340 | applic function graphen oxid base biosensor health monitor simpl graphen deriv print platform biosensor hold great potenti revolution person medicin environment monitor construct key factor depend either manufactur techniqu robust sens materi improv efficaci devic function graphen attract choic transduc materi due various advantag interfac biorecognit element graphen deriv graphen oxid go thus use extens biosensor monitor diseas addit graphen pattern varieti structur incorpor biosensor devic microfluid devic electrochem plasmon sensor among biosens materi go gain much attent due easi synthesi process pattern featur high function high electron transfer properti larg surfac area lead sensit point use applic consid demand recent challeng perspect review attempt describ state art biosensor base function graphen special emphasi given elucid mechan sens discuss differ applic describ futur prospect function go base biosensor health care environment monitor focus addit manufactur print | D015374;D006108;D066330 | T109;T073;T196;T075;T059 |
34,677,339 | fibr optic surfac plasmon reson biosensor monoclon antibodi titer quantif extraordinari optic transmiss fibr optic surfac plasmon reson biosens platform engin improv portabl sensit appli monitor concentr monoclon antibodi mab refin fabric procedur chang materi flow cell compon optic fibr biosensor portabl robust extern interfer implement effect templat clean procedur precis control fabric process consist sensit nm per refract index unit nmriu achiev biosensor detect mab limit detect lod gml result show biosensor potenti tool rapid quantif mab titer biosensor regener least time mm glycin ph consist signal chang obtain regener moreov employ spacer arm sm peg use immobilis protein onto gold film demonstr unabl improv detect sensit thus simpl procedur without spacer arm could use prepar protein base biosensor result demonstr fibr optic surfac plasmon reson biosensor compet real time line monitor antibodi titer futur process analyt technolog pat tool bioprocess develop manufactur therapeut antibodi | D015374;D020349 | T059;T063;T075 |
34,677,338 | nanozym particip biosens pesticid cholinesteras critic review improv output qualiti agricultur product pesticid global util effici tool protect crop insect howev given pesticid use difficult decompos inevit remain agricultur product enrich food chain ecosystem pose great threat human health environ thus develop effici method tool monitor pesticid residu relat biomark acetylcholinesteras butylcholinesteras becam quit signific advantag excel stabil tailor catalyt perform low cost easi mass product nanomateri enzym like properti nanozym extens util field rang biomedicin environment remedi especi catalyt natur offer amplifi signal high sensit detect nanozym find potenti applic sens various analyt includ pesticid biomark highlight progress field sens principl pesticid cholinesteras base nanozym catalysi definit summar emerg detect method technolog particip nanozym critic discuss import typic exampl introduc reveal promis use nanozym also challeng field futur trend propos hope inspir effort advanc nanozym involv sensor pesticid cholinesteras | D015374;D002802;D049329;D010575 | T116;T073;T131;T075;T059;T126 |
34,677,337 | smartphon base chemiluminesc origami pad rapid assess glucos blood level microfluid paper analyt devic pad repres one appeal trend develop simpl inexpens analyt system diagnost applic point care poc herein describ smartphon base origami pad quantit determin glucos blood sampl base glucos oxidas catalyz oxid glucos lead hydrogen peroxid detect mean luminolhexacyanoferr iii chemiluminesc cl system exploit foldabl pad format two step analyt procedur implement first dilut blood sampl ad hydrogen peroxid accumul biosensor fold transport buffer ad bring hydrogen peroxid contact cl reagent thus promot cl reaction enabl poc applic reagent requir assay preload pad chemic handl requir print portabl devic develop measur cl emiss use smartphon cmos camera pad stabl day storag room temperatur assay display limit detect mol l prove abl identifi hypoglycem hyperglycem blood sampl less min | D056656;D008163;D000068997 | T059;T073;T075 |
34,677,336 | mesopor one compon gold microshel ser substrat surfac enhanc raman scatter ser power analyt tool label free analysi found broad spectrum applic materi chemic biomed scienc recent year great interest wit ration design ser substrat amplifi raman signal option allow select detect analyt especi essenti challeng biomed applic studi hard templat nobl metal propos novel approach design one compon tailor made ser platform porous au microparticl fabric via dual ex situ adsorpt au nanoparticl situ reduct haucl mesopor sacrifici microcryst vaterit caco elimin microcryst mild condit result format stabl mesopor one compon au microshel ser perform microshel low w laser power probe use rhodamin b bovin serum albumin show enhanc factor respect propos strategi open broad avenu design scalabl fabric one compon porous metal particl serv superior ser platform possess excel plasmon properti possibl select inclus analyt molecul andor ser nanotag high specif ser analysi | D006046;D053768 | T121;T073;T196 |
34,677,335 | algin bead biosystem determin lactat sweat use imag analysi lactat present sweat high concentr metabolit high interest sport scienc medicin therefor potenti determin lactat concentr physiolog fluid point need minim invas valuabl work synthesi perform algin bead biosystem investig artifici sweat differ lactat concentr use proof concept lactat detect base colorimetr assay imag analysi method use lactat oxidas horseradish peroxidas tetramethyl benzidin reaction mix lactat artifici sweat detect r linear rang mm mm limit detect mm limit quantif mm real sweat sampl use proof concept test perform biosystem obtain lactat concentr mm novel sens configur use algin bead give fast reliabl method lactat sens could integr complex analyt system | D019344;D013542 | T031;T121;T109;T123 |
34,677,334 | aptam embed arch cruciform dna assembl vs scaffold sensit detect breast cancer cell arch cruciform dna self assembl aunpsv scaffold high sensit select electrochem biosensor michigan cancer foundat mcf breast cancer cell construct arch dna form use two singl strand dna sequenc embed aptam mcf cell absenc mcf cell cruciform dna label three termin biotin bound top arch dna combin streptavidin label horseradish peroxidas hrp catalyz hydroquinon h reaction electrod surfac presenc mcf cell releas cruciform dna reduc amount immobil hrp thus effect inhibit enzym mediat electrocatalysi electrochem respons sensor negat correl concentr mcf cell linear rang cellsml limit detect low cellsml sn two dimension materi enzym base dual signal amplif biosensor may pave new way high sensit detect tumor cell real sampl | D052157;D015374;D001943;D053768 | T191;T073;T114;T075;T059 |
34,677,333 | high sensit terahertz biosensor base mode coupl graphenebragg reflector hybrid structur work high sensit terahertz thz biosensor achiev use graphenebragg reflector hybrid structur high sensit thz biosensor develop sharp fano reson transmiss peak creat coupl graphen tamm plasmon gtps mode defect mode found propos thz biosensor high sensit fermi energi graphen well thick refract index sens medium specif paramet set composit structur achiev liquid biosensor gas biosensor liquid biosensor maximum sensit nbsp nbsp riu obtain select appropri paramet believ propos layer hybrid structur potenti fabric graphen base high sensit biosensor | D015374;D006108 | T109;T059;T196;T075 |
34,677,332 | design analysi singl system impedimetr biosensor detect mosquito born virus treatment mosquito born viral diseas dengu virus denv zika virus zikv chikungunya virus chikv becom difficult due delay diagnosi process addit share transmiss media similar symptom earli stage infect diseas becom critic earli diagnosi overcom common platform identifi virus high sensit select even differ serotyp high demand studi attempt electrochem impedimetr method detect zikv denv chikv use correspond antibodi conjug sensor electrod signific method emphas fabric common matrix gold polyanilin sulfur nitrogen dope graphen quantum dot nanocomposit au pani n gqds strong impedimetr respons base conjug antibodi result minimum cross reactiv detect various mosquito born virus separ result four serotyp denv zikv chikv detect success lod femtogram ml | D015374;D065632;D002646;D009033;D003715;D003716;D000079426;D000071244;D000071243 | T047;T005;T204;T075;T059 |
34,677,331 | paper base airborn bacteria collect dna extract kit critic risk airborn infecti diseas bio weapon harm bacteria current highest ever human histori requir monitor airborn pathogen gradual increas defend bioterror prevent pandem especi via simpl low cost platform appli resourc limit set develop paper base airborn bacteria collect dna extract kit suitabl simpl applic minim instrument airborn sampl collect dna extract pcr analysi integr paper kit creat easi use paper base air monitor system use print technolog combin air pump oper time entir process compris air sampl bacteri cell lysi purif concentr dna elut dna analyt within min investig optimum set test custom design close cabinet system fabric cabinet system paper kit oper effect temperatur c relat humid air contain cfu staphylococcus aureus paper kit could appli simpl rapid cost effect airborn pathogen monitor | D000391;D001419;D004269 | T007;T114;T067 |
34,677,330 | singl substrat biosensor spin coat liquid crystal film simpl sensit label free protein detect liquid crystal lc base singl substrat biosensor develop spin coat lc thin film dimethyloctadecyl trimethoxysilyl propyl ammonium chlorid dmoap decor glass slide compar convent sandwich cell configur simplifi procedur prepar lc film allow film thick precis control adjust spin rate thus elimin person error involv lc cell assembl limit detect lod bovin serum albumin bsa lower gml thick sandwich cell commerci lc e gml thick spin coat e film gml reduc e film thick moreov exploit lc film high birefring nemat lc hdn immunodetect cancer biomark ca lod compar determin sandwich hdn cell achiev gml ca use captur antibodi concentr order magnitud lower lc cell result suggest employ spin coat lc film instead convent sandwich lc cell provid reliabl reproduc cost effect singl substrat platform allow simpl fabric lc base biosensor sensit label free protein detect immunoassay | D015374;D050866 | T059;T104;T073;T075 |
34,677,328 | recent advanc iot assist wearabl sensor system healthcar monitor iot play essenti role mani industri last decad recent advanc healthcar industri made possibl make healthcar access peopl improv overal health next step healthcar integr iot assist wearabl sensor system seamless review rigor discuss various iot architectur differ method data process transfer comput paradigm compil various communic technolog devic common use iot assist wearabl sensor system deal various applic healthcar advantag world compar analysi wearabl technolog healthcar also discuss tabul various research technolog review also analys problem common face iot assist wearabl sensor system specif issu need tackl optim system healthcar describ various futur implement made architectur technolog improv healthcar industri | D000076251 | T073 |
34,677,327 | versatil cell anim model advanc investig lead poison heavi metal lead pb irrevers damag human nervous system help understand pb induc damag appli genet encod frster reson energi transfer fret base pb biosensor met lead two live system monitor concentr pb induc pluripot stem cell ipsc deriv cardiomyocyt semi tissu platform drosophila melanogast fruit fli vivo anim model differ fret imag modal use obtain fret signal repres presenc pb test sampl differ spatial dimens use ipsc deriv cardiomyocyt relationship beat activ beat per minut bpm determin fluctuat fluoresc signal concentr pb repres fret emiss ratio valu met lead reveal simultan measur pb affect beat activ cardiomyocyt wherea two drug stop entri pb differenti affect beat activ verapamil revers cessat beat wherea apb partial restor activ bpm result clear demonstr potenti biosensor system anti pb drug screen applic drosophila model pb detect within adult brain larval central nervous system cha gal ua met lead use fast epifluoresc high resolut two photon fret ratio imag system tissu specif express pb biosensor provid excel opportun explor possibl pb specif popul within live organ believ integr pb biosensor system appli prevent pb poison advanc research pb neurotoxicolog | D015374;D007855 | T059;T037;T075 |
34,677,326 | sub part per billion level sens fentanyl residu wastewat use portabl surfac enhanc raman scatter sens detect illicit drug residu wastewat provid new rout toward communiti level assess drug abus critic public health howev tradit chemistri analyt tool high perform liquid chromatographi tandem mass spectrometri hplc ms meet larg scale test requir term cost prompt conveni use articl demonstr ultra sensit portabl surfac enhanc raman scatter sens ser fentanyl synthet opioid sewag water achiev quantit analysi princip compon analysi partial least squar regress ser substrat adopt applic synthes situ growth silver nanoparticl diatomac earth film show ultra high sensit part per trillion artifici contamin tap water lab use commerci portabl raman spectromet base train data artifici contamin tap water predict fentanyl concentr sewag water wastewat treatment plant part per billion ppb comparison hplc ms confirm fentanyl concentr ppb fail provid specif valu concentr sinc concentr low addit prove valid ser sens techniqu compar ser result multipl sewag water treatment plant result consist public health data local health author ser sens techniqu ultra high sensit sub ppb level prove feasibl point care detect illicit drug sewag water crucial assess public health | D005283;D053768 | T121;T073;T109 |
34,677,324 | dispos voltammetr sensor modifi block copolym dispers graphen simultan determin dopamin ascorb acid ex vivo mous brain tissu dopamin da ascorb acid aa two import biomark similar oxid potenti facilit simultan electrochem detect new voltammetr sensor develop modifi screen print carbon electrod spce newli synthes block copolym poli dmaema b styren pd b dispers reduc graphen oxid rgo prepar pd b rgo modifi spce character use rang physic electrochem techniqu includ raman spectroscopi scan electron microscopi transmiss electron microscopi cyclic voltammetri electrochem imped spectroscopi linear sweep voltammetri compar bare spce pd b rgo modifi spce pd b rgospc show better sensit peak peak separ da aa mix solut optimum condit dynam linear rang da aa detect limit sn respect furthermor pd b rgospc exhibit consider enhanc anti interfer capabl high reproduc storag stabil four week practic potenti pd b rgospc sensor measur da aa demonstr use ex vivo brain tissu parkinson diseas mous model control | D001921 | T023 |
34,677,323 | optic biosensor platform display vari sensit direct detect influenza rna detect method requir nucleic acid amplif advantag viral diagnost due rapid result platform could provid inform accur diagnos pandem surveil influenza virus prone pandem induc genet mutat need appli detect platform influenza diagnost analyz fast evalu viral emerg risk fever pipelin ultrasensit detect platform includ waveguid base optic biosensor flow cytometri bead base assay pipelin also evalu silico sequenc coverag comparison us center diseas control prevent cdc influenza b diagnost assay influenza fever probe design higher toler mismatch base cdc probe fever probe altogeth higher detect rate influenza isol sequenc genbank format use molecular beacon fever probe detect influenza rna low nm waveguid base optic biosensor nm flow cytomet addit molecular beacon inher high background signal also develop exonucleas select method could detect pm rna combin high coverag probe develop use fever pipelin coupl ultrasensit optic biosensor promis approach futur influenza diagnost biosurveil applic | D007251;D021141 | T047;T059;T063 |
34,677,322 | fpga base machin learn tool situ food qualiti track use sensor fusion continu develop accur select bio chemo sensor led grow use sensor array differ field health monitor cell cultur analysi bio signal process food qualiti track analysi inform extract amount data provid sensor array possibl base machin learn techniqu appli sensor fusion howev comput solut implement cost bulki comput limit use situ scenario outsid complex laboratori facil work present applic machin learn techniqu food qualiti assess use singl field programm gate array fpga chip characterist low cost low power consumpt well low size allow applic propos solut even space constrain place food manufactur chain exampl propos system test e nose develop beef classif microbi popul predict | D005504;D012815 | T059;T066 |
34,677,321 | distinguish amyloid protein mous model alzheim diseas label free vibrat imag due increas averag age human alzheim diseas ad becom one disord highest incid worldwid abnorm amyloid protein accumul believ common caus ad therefor distinguish lesion area provid clue ad diagnosi present optic spectroscopi imag approach base coher anti stoke raman scatter car label free vibrat imag mous model ad perform distinguish lesion area studi spectra region without plaqu raman spectra non region exhibit specif differ intens ratio wave peak detect cm non region ratio peak intens cm cm approxim wherea region label free vibrat imag may provid new method clinic diagnosi basic research ad | D000544 | T048;T047 |
34,677,320 | advanc nanotechnolog base biosens immunoregulatori cytokin cytokin larg group small protein secret immun non immun cell respons extern stimuli much attent given applic cytokin detect earli diseas diagnosismonitor therapeut respons assess date wide rang assay avail cytokin detect howev specif applic multiplex continu measur cytokin wearabl biosens devic high desir effort various nanomateri extens investig due extraordinari properti high surfac area control particl size shape lead tunabl optic emiss electr magnet properti differ type nanomateri nobl metal metal oxid carbon nanoparticl explor various biosens applic advanc nanomateri synthesi devic develop led signific progress push limit cytokin detect articl review current use method cytokin detect new nanotechnolog base biosensor ultrasensit cytokin detect | D015374;D016207 | T129;T059;T116;T075 |
34,677,319 | optic smartphon base inspect platform identif diseas orchid infect orchid odontoglossum ringspot virus cymbidium mosaic virus caus orchid disfigur substanti sourc econom loss orchid farm although immunoassay identifi infect immunoassay expens time consum labor consum limit sampl base test method studi propos noncontact inspect platform use spectromet android smartphon orchid leav illumin handheld optic probe android app base internet thing artifici intellig display measur floresc spectrum determin infect status within use algorithm host remot server algorithm train optic data result polymeras chain reaction assay test accuraci algorithm area receiv oper characterist curv thus platform algorithm accur conveni infect screen orchid | D029595;D000068997 | T002;T073 |
34,677,318 | surfac plasmon reson proteas detect integr homogen reaction heterogen assay proteas usual requir immobil peptid substrat solid surfac enzymat hydrolysi reaction howev immobil peptid solid surfac may caus steric hindranc prevent interact substrat activ center proteas thus limit enzymat cleavag peptid work report heterogen surfac plasmon reson spr method proteas detect integr homogen reaction sensit enhanc signal amplif streptavidin sa conjug immunoglobulin g sa igg caspas cas determin model peptid label two biotin tag n c termin bio gdevdgk bio use substrat absenc cas substrat peptid captur neutravidin na cover spr chip facilit attach sa igg avidin biotin interact howev peptid substrat digest cas aqueous phase product bio gdevd gk bio would compet substrat bond na chip surfac thus limit attach sa igg method integr advantag heterogen homogen assay use determin cas inhibitor evalu cell apoptosi satisfactori result | D020349 | T063 |
34,677,317 | novel micro nano optoelectron biosensor label free real time biofilm monitor accord world health organ forecast antimicrobi resist amr expect becom one lead caus death worldwid follow decad rise danger amr caus overus antibiot becom ineffect mani pathogen particular presenc bacteri biofilm context non destruct label free techniqu real time studi biofilm generat matur togeth analysi effici antibiot high demand propos design novel optoelectron devic base dual array interdigit micro nanoelectrod parallel aim monitor bacteri biofilm evolut use optic electr measur optic respons given nanostructur base guid mode reson effect q factor normal reson amplitud allow high spatial resolut analysi interact plankton bacteria distribut small coloni role biofilm generat calcul reson wavelength shift variat nm presenc bacteria surfac electr respons micro nanoelectrod necessari studi metabol state bacteria reveal efficaci antibiot destruct biofilm measur current chang na thick biofilm destroy respect absenc biofilm | D018441;D015374;D004784 | T007;T059;T057;T075 |
34,677,316 | recent progress electrochem immunosensor biosensor use medic diagnosi work analyz physiolog fluid antibodi frequent use molecular recognit molecul specif bind target analyt complex biolog solut electrochemistri introduc measur quantit signal transduc bound analyt mani reason includ good sensit recent numer electrochem immunosensor develop various strategi propos detect biomark paper recent progress electrochem immunosensor review particular focus immobil method use antibodi voltammetr amperometr impedimetr electrochemiluminesc immunosensor | D015374;D055664 | T059;T075 |
34,677,315 | nanosystem biosens prototyp effici diagnost special issu honor professor bansi malhotra proven rapid bioinformat analysi accord patient health profil addit biomark detect low level emerg essenti design analyt diagnost system manag health intellig person manner object need optim combin nano enabl sens prototyp artifici intellig ai support predict analysi internet medic thing iomt base bioinformat analysi develop system began prototyp demonstr effici diseas diagnost perform futur diseas manag approach explor aspect special issu plan nano micro technolog section mdpi biosensor journal honor acknowledg contribut prof bd malhotra phd fna fnasc made field biosensor | D015374;D036103 | T059;T090;T075 |
34,677,314 | millimet wave base spoof local surfac plasmon reson sens glucos concentr glucos monitor sensor necessari extens studi prevent control health problem caus diabet spoof local surfac plasmon lsp reson sensor investig chemic sens biosens spoof lsp similar characterist lsp microwav terahertz frequenc rang certain advantag high qualiti factor improv sensit general microwav spoof lsp reson base glucos sensor studi studi millimet wave base spoof surfac plasmon reson sensor design measur glucos concentr millimet wave base sensor smaller chip size higher sensit microwav frequenc sensor therefor microfluid channel design reusabl abl oper small sampl volum align polydimethylsiloxan channel simultan fabric use multilay bond film attach upper side pattern concentr electromagnet field real time sensor detect glucos concentr via chang paramet oper ghz averag sensit db mgdl within mgdl rang minimum detect concentr distinguish signal mgdl db respect l sampl reusabl reproduc assess replic | D015374;D001786 | T059;T109;T075 |
34,677,313 | high sensit luminesc bioassay use recombin escherichia coli biosensor rapid detect low cr vi concentr environment water studi construct recombin escherichia coli strain differ promot insert chromat sens regul chrb report gene luxab sens low hexaval chromium cr vi concentr mgl subsequ biosensor characterist sensit select specif measur cr vi various water bodi evalu luminesc intens biosensor depend ph temperatur detect time coexist carbon sourc coexist ion cr vi oxyanion form cr vi concentr cell type type medium recombin lux express e coli promot lux e coli limit detect lod mgl highest luminesc intens sensit cr vi detect follow e coli promot lu x e coli lod mgl sp promot sp lux e coli lod mgl biosensor could use determin whether cr vi standard met term water qualiti even use thaw frozen cell biosensor day cryogen storag sp lux e coli biosensor shortest detect time h highest adapt environment interfer lux e coli biosensor optim lod wide measur rang mgl low deviat detect cr vi industri effluent domest effluent surfac water effici cr vi biosensor unpreced studi evalu recombin lux e coli dissimilar promot possibl practic cr vi measur water bodi biosensor perform clear superior past system term detect time lod detect deviat real water sampl | D015374;D004784 | T059;T057;T075 |
34,677,311 | high perform passiv plasma separ ost pillar forest plasma separ high interest later flow test use whole blood sampl liquid built passiv microfluid devic plasma separ high perform devic made blood filtrat membran stoichiometri thiol ene ost pillar forest ost pillar forest fabric doubl replica mold laser cut polymethylmethacryl pmma mold uniform microstructur devic util filtrat membran separ plasma whole blood sampl use hydrophil ost pillar forest capillari pump propel plasma devic use separ blood plasma high puriti later use later flow test devic process l whole blood achiev plasma separ yield high protein recoveri rate separ plasma par state art technolog devic develop later flow test biomark detect whole blood | D056656;D046210 | T059;T075 |
34,677,310 | bio specif auf porous spongi nanoclust sensit ser detect escherichia coli h sensit fast detect escherichia coli h organ inorgan hybrid auf nanoclust ncs synthes first time use gold nanoparticl gnps bovin serum albumin ferric chlorid phosphat buffer salin antibodi auf porous spongi ncs larg surfac area show excel bio specif capabl e coli h gnps auf ncs function signal enhanc signific increas raman signal via metathesi reaction product prussian blue obvious improv detect sensit combin novel auf ncs antibodi modifi magnet nanoparticl creat biosensor capabl sensit detect e coli h show good linear respons cfuml high detect sensit cfuml good recoveri rate spike food sampl result make biosensor well suit food safeti monitor strategi achiev goal sensit quantit detect e coli h | D055664;D019453;D005516 | T007;T059;T067 |
34,677,309 | determin particl size posit coplanar electrod setup use measur opac microfluid cytometri microfluid imped flow cytomet enabl high throughput non invas label free detect singl cell cytomet coplanar electrod easi cheap fabric sensit posit differ pass particl owe inhomogen electr field present novel particl height compens method employ depend measur electr opac particl height measur electr opac correl particl height result constant electr doubl layer seri capacit electrod altern exist compens method use two coplanar electrod multi frequenc analysi determin particl size mixtur polystyren bead accuraci cv respect addit predict bead height accuraci channel height use measur opac demonstr applic flow cytometri yeast use two electrod special interest simplifi easi use chip minimum amount instrument limit size | D046210 | T059 |
34,677,308 | roll circl amplif effici analyt tool rapid detect contamin aqueous environ environment contamin global concern effect strategi remedi develop rapid site afford monitor method howev remain challeng especi regard detect various contamin complex water environ applic molecular method recent attract increas attent exampl roll circl amplif rca isotherm enzymat process short nucleic acid primer amplifi form long singl strand nucleic acid use circular templat special nucleic acid polymeras furthermor approach engin devic point need monitor environment pollut paper describ fundament principl rca advantag disadvantag rca assay discuss recent develop rca base tool environment analysi determin various target includ heavi metal organ small molecul nucleic acid peptid protein even microorgan aqueous environ final summar challeng outlin strategi advanc techniqu applic contamin monitor | D004784 | T057 |
34,677,306 | mitig data packet loss bluetooth low energi base wearabl healthcar ecosystem bluetooth low energi ble play critic role wireless data transmiss wearabl technolog previous work field most focus optim transmiss throughput power consumpt howev much work report systemat evalu data packet loss ble wearabl healthcar ecosystem essenti reliabl secur data transmiss consid divers wearabl devic use peripher shelf smartphon android iphon raspberri pi various chipset oper system os hub wearabl ecosystem urgent need understand factor influenc data loss ble develop mitig solut address data loss issu work systemat evalu packet loss android io base wearabl ecosystem propos reduc transmiss frequenc data bundl strategi along queue base packet transmiss protocol mitig data packet loss ble propos protocol provid flexibl peripher devic work host either real time mode time data transmiss offlin mode accumul data transmiss request host test result show lower transmiss frequenc data bundl reduc packet loss less queue base packet transmiss protocol elimin remain packet loss use request routin data loss mitig protocol develop research wide appli ble base wearabl ecosystem various applic bodi sensor network bsn internet thing iot smart home | D003695;D059015 | T058;T093;T073 |
34,677,277 | oment macrophag crown like structur associ poor prognosi advanc stage serous ovarian cancer tumor microenviron well recogn framework immun cell present tumor microenviron promot inhibit cancer format develop crown like structur cls report die dead adipocyt surround crown macrophag within adipos tissu histolog hallmark inflammatori process tissu clss also found relat format progress prognosi type cancer howev presenc clss omentum advanc stage high grade serous ovarian carcinoma hgsoc thorough investig use cd pan macrophag marker cd like polar macrophag marker immunohistochemistri ihc perform identifi tumor associ macrophag tam clss retrospect studi analyz patient advanc stage hgsoc receiv complet treatment avail clinic data juli decemb nation cheng kung univers hospit nckuh tainan taiwan base multivari cox regress analysi patient oment cd clss poor os median surviv vs month p hazard ratio hr confid interv ci patient oment cd clss also poor os median surviv vs month hr ci p addit patient oment cd cd clss show poor pfs median surviv vs month hr ci p median surviv vs month hr ci respect p convers densiti cd cd tam ovarian tumor associ patient prognosi advanc stage hgsoc cohort conclus first time demonstr presenc oment clss associ poor prognosi advanc stage hgsoc | D009852;D010051 | T191;T023 |
34,677,276 | total colectomi part ultra radic surgeri ovarian cancer short long term outcom background aim studi assess outcom patient underw total colectomi tc part surgeri ovarian cancer oc method perform retrospect analysi oc patient residu diseas rd report use sugarbak complet cytoreduct score result forti two patient underw tc primari debulk surgeri pds four ten patient underw tc interv debulk surgeri id secondari cytoreduct respect median overal surviv mos oc patient follow pds month cc resect month cc resect month cc resect p sever advers event report patient id group two patient surviv year id one patient die month recurr oc group mos month patient age year associ shorten overal surviv os presenc advers event conclus tc part ultra radic surgeri advanc oc result high rate optim debulk howev surviv benefit observ patient macroscop diseas | D020360;D010051 | T191;T061 |
34,677,275 | effect safeti first line pembrolizumab older adult pd l posit non small cell lung cancer retrospect cohort studi alberta immunotherapi databas emerg immunotherapi revolution treatment non small cell lung cancer nsclc multipl landmark clinic trial establish efficaci agent howev mani patient receiv immunotherapi clinic practic would consid clinic trial inelig one popul often repres clinic trial older adult current studi evalu clinic safeti outcom popul overal older adult year age younger adult compar clinic outcom equival object respons rate orr time treatment failur ttf median overal surviv p p p respect furthermor safeti outcom equival cohort similar rate immun relat advers event ira ira relat hospit caus hospit p p p respect older age found impact overal surviv multivari analysi reveal poor eastern cooper oncolog group ecog status low bodi mass index bmi poorintermedi lung immun prognost index lipi associ wors surviv conclus age impact efficaci safeti pembrolizumab nsclc therefor advanc age deterr treat patient pembrolizumab physician care provid thus focus factor may influenc therapeut outcom | D002289;D008175 | T191 |
34,677,274 | chang health state util valu japanes patient end stage breast cancer aim determin dynam trend health state util valu hsuv patient end stage breast cancer select patient compris primari breast cancer pbc metastat breast cancer mbc survivor patient mbc death hsuv patient pbc mbc survivor month respect end observ period valu respect mbc deceas aforement period root mean squar error rmse decreas hsuv month patient pbc mbc survivor mbc deceas respect one way analysi varianc differ absolut error among group signific p multipl comparison indic differ absolut error patient pbc mbc deceas p patient end stage breast cancer well control hsuv month death sharp declin hsuv month lead death | D001943 | T191 |
34,677,273 | heart emot consequ conceptu caregiv report outcom context colorect cancer colorect cancer crc demand primari caregiv yet insuffici evid describ caregiv report outcom cros matter caregiv cros refer caregiv assess health status result support patient studi purpos describ emot impact caregiv patient crc import caregiv attribut emot chang diagnosi throughout treatment guid qualit interpret descript analyz caregiv crc patient interview either individu caregiv patient dyad six interview use induct code constant compar techniqu found emot aspect care patient crc heart caregiv caregiv experi engend emot consequ includ face patient life chang diagnosi uncertain futur need patient throughout never end nightmar treatment bear wit patient suffer worn unrel caregiv respons navig relationship endur unwant chang broad rang emot import caregiv contribut comprehens foundat evid futur conceptu use cros | D017028;D015179 | T097;T191;T098;T099 |
34,677,272 | consider develop reassess process report canadian real world evid valu cancer drug canrevalu collabor reassess uptak work group canadian real world evid valu cancer drug canrevalu collabor establish develop framework generat use real world evid rwe inform reassess cancer drug follow initi health technolog assess hta reassess uptak work group rwg one five establish canrevalu work group rwg aim develop consider incorpor rwe hta reassess strategi use rwe reassess drug fund decis februari decemb rwg attend four teleconfer follow survey two person meet discuss recommend develop reassess process potenti barrier facilit modifi delphi method use gather input draft report recommend decemb share public consult decemb januari initi consider develop reassess process propos specif reassess initi divers stakehold includ decis maker public drug plan industri stakehold reassess process model exist deliber recommend framework use hta agenc propos reassess outcom categori includ maintain status quo revisit fund criteria renegoti price disinvest overal initi consider serv basi futur advanc collabor | D000970;D009369 | T191;T121;T109 |
34,677,271 | singl center comparison cu dotaga psma f psma pet ct imag prostat cancer diagnost perform cu dotaga psma pet ct imag compar retrospect f psma pet ct prostat cancer patient recurr diseas primari stage select patient advanc local possibl metastat diseas | D000072078;D011471 | T191;T060 |
34,677,270 | pretreat neutrophil lymphocyt ratio predict marker respons atezolizumab plus bevacizumab hepatocellular carcinoma combin therapi anti program death ligand monoclon antibodi atezolizumab plus anti vascular endotheli growth factor agent bevacizumab atezobev approv first line treatment unresect hepatocellular carcinoma hcc atezobev therapi relat well toler howev factor predict respons yet report thus aim investig whether pretreat neutrophil lymphocyt ratio nlr could predict therapeut respons patient hcc treat atezobev therapi | D006528;D008113 | T191 |
34,677,269 | exercis reduc anthracyclin mediat cardiovascular complic breast cancer survivor develop cancer therapeut great reduc morbid mortal femal breast cancer come cost increas risk cardiovascular complic particular anthracyclin like doxorubicin mainstay current chemotherapi regimen associ dose depend cardiotox exercis wide accept effect intervent reduc cardiovascular risk varieti differ clinic condit howev benefit exercis anthracyclin mediat cardiotox clear understood first review discuss pre clinic studi elucid cardioprotect mechan aerob resist exercis improv cardiovascular function set anthracyclin treatment next aim summar result aerob resist exercis clinic trial conduct femal breast cancer receiv anthracyclin base chemotherapi review discuss current exercis guidelin women undergo chemotherapi contraind exercis final review address gap research specif need clinic trial establish recommend exercis prescript within patient popul | D001943;D000073116;D006331 | T191;T047;T101;T201 |
34,677,268 | neoadjuv therapi lung cancer import object respons rate major patholog respons lung cancer fatal frequent diagnos malign tumor neoadjuv therapi promis approach prolong surviv increas chanc cure rate patient potenti resect diseas current mani therapeut altern includ chemotherapi target therapi immunotherapi continu explor enrich content neoadjuv therapi howev neoadjuv therapi remain unifi evalu standard overal surviv os gold standard evalu clinic benefit cancer treatment need year reliabl evalu henc research need identifi surrog endpoint predict os accur reliabl without long follow period review describ research progress differ neoadjuv therapi explor respons evalu aim identifi stronger predictor os | D002289;D008175 | T191 |
34,677,267 | impact split dose first rituximab infus patient high lymphocyt count common advers reaction rituximab infus relat reaction irr evalu efficaci split dose first rituximab infus two day reduc irr incid patient hematolog cancer high lymphocyt count retrospect observ studi conduct two healthcar center quebec canada studi enrol patient white blood cell count l receiv first rituximab dose hematolog cancer decemb may one healthcar center use asymmetr split dose use symmetr split dose total treatment episod collect patient among patient receiv fraction dose schedul develop irr first rituximab infus compar standard protocol adjust relat risk p signific differ observ irr sever either group howev patient receiv asymmetr protocol develop irr compar symmetr protocol adjust relat risk p result suggest asymmetr split dose could effect reduc incid irr prefer symmetr one | D000069283 | T129;T121;T116 |
34,677,266 | incid etiolog prevent manag ureteroenter strictur robot assist radic cystectomi review publish evid person experi benign ureteroenter anastomosi strictur uess one mani critic complic may caus irrevers disabl follow robot assist radic cystectomi rarc previous studi shown incid rate ue rarc reach rarc higher ue incid rate compar open radic cystectomi various known unknown factor involv occurr ue minim incid ue rarc group standard procedur techniqu intracorpor urinari divers appli follow five strategi wide delic dissect uret preserv periureter tissu gentl handl uret secur periureter tissu anastomot site use indocyanin green confirm good blood suppli standard ampl ureter spatul length wallac ureteroenter anastomosi object measur develop institut standard procedur manual review focus incid etiolog prevent manag ue rarc bring attent incid complic also propos standard surgic procedur minim incid rarc | D012371;D014513;D001749 | T191;T023;T090 |
34,677,265 | immunotherapi extens stage small cell lung cancer small cell lung cancer sclc remain poor understood diseas aggress featur high relaps rate signific morbid well mortal yet persist limit treatment option three decad treatment algorithm sclc stagnant despit multipl attempt find altern therapeut option could improv respons increas surviv rate hand immunotherapi thrive concept revolution treatment option multipl malign render previous untreat diseas potenti curabl extens stage sclc immunotherapi signific alter cours diseas part treatment algorithm first line set nevertheless import question aris best implement immunotherapi would benefit final enhanc respons | D008175;D055752 | T191 |
34,677,264 | synaptotagmin high express estrogen receptor posit breast cancer accumul evid indic tumor promot role synaptotagmin syt sever cancer howev studi investig express breast cancer bc studi aim clarifi signific syt bc | D001943;D011960 | T192;T191;T116 |
34,677,263 | recent advanc photodynam imag therapi hepatobiliari malign clinic experiment aspect therapeut diagnost modal light well known deriv photodynam reaction photosensit pss specif wavelength light exposur exist tissu oxygen develop sinc th centuri photodynam therapi pdt effect local treatment cancer specif laser ablat malign organ includ bile duct although curabl extrahepat cholangiocarcinoma expect surgeri alon patient unresect remnant biliari cancer need effect palliat therapi includ pdt effect pdt cholangiocarcinoma report experiment clinic standard option due problem accompani photosensit limit access rout irradi tumor hypoxia etc novel deriv treatment photoimmunotherapi appli field hepatobiliari system photodynam diagnosi pdd wide appli clinic diagnos liver malign liver vascular present aminolevulin acid ala indocyanin green icg dye main use pss pdd icg appli detect liver malign vascular howev ideal tool combin pdd pdt solid tumor includ hepatobiliari malign clinic develop proceed experiment clinic trial necessari clarifi effect photosensit drug feasibl photochem diagnosi local treatment | D001650;D018281 | T191 |
34,677,262 | breast cancer surgeri new issu sinc ancient time breast cancer treatment crucial reli surgeon clinician make great effort find increas conserv approach cure tumor halstedian era mid late th centuri predomin practic consist radic disfigur remov breast much detriment women psycho physic well thank enlighten scientist professor umberto veronesi breast cancer surgeri sinc impress progress adopt much conserv approach last three decad better understand tumor biolog signific biomark made assess genet molecular profil increas import time neo adjuv treatment introduc great improv genet imag technolog oncolog reconstruct surgic techniqu made futur breast cancer manag must rest ever precis target type surgeri increas multidisciplinari person approach ensur oncolog radic offer best possibl qualiti life | D001943 | T191 |
34,677,261 | examin pathoplast moder role educ associ depress mood self rate health among cancer survivor popul base studi self rate health srh salient patient outcom cancer survivor depress mood educ known determin cancer survivor srh move beyond well establish direct associ depress mood educ srh among cancer survivor epidemiolog studi investig pathoplast role educ depress mood relat srh among nation repres sampl cancer survivor unit state | D000073116;D009369 | T191;T101;T201 |
34,677,260 | influenc adjuv chemotherapi dose intens five year outcom resect colon cancer singl centr retrospect analysi evid achiev dose intens adjuv colon cancer treatment improv surviv total consecut patient resect stage iii high risk stage ii colon cancer receiv adjuv chemotherapi retrospect analyz patient receiv least week adjuv therapi includ primari object assess influenc dose index di relat dose intens rdi dfs os year patient receiv fluorouracil base doublet therapi oxaliplatin folfox fu oxaliplatin assess separ capecitabin monotherapi capecitabin group dfs rate year respect os rate respect receiv folfox dfs rate year respect os rate year respect median rdi capecitabin oxaliplatin fu compon respect base multivari analysi patient receiv folfox oxaliplatin di improv dfs os compar oxaliplatin di otherwis signific differ dfs os compar patient achiev rdi di versus patient receiv adjuv chemotherapi resect colon cancer | D003110;D009944 | T191;T109 |
34,677,259 | multifoc multicentr breast cancer comparison effici mammographi contrast enhanc spectral mammographi magnet reson imag group patient primarili oper breast cancer multifoc multicentr breast cancer mfmcc signific aspect determin specialist choic appli breast conserv therapi bct perform mastectomi studi aim assess use mammographi mg contrast enhanc spectral mammographi cesm magnet reson imag mri women diagnos breast cancer qualifi surgic intervent visual addit cancer foci | D001943 | T191 |
34,677,258 | role navig radiofrequ ablat devic concurr vertebr augment treatment difficult reach spinal metastas purpos studi assess effect navig radiofrequ ablat devic concurr vertebr augment treatment posterior vertebr bodi metastat lesion technic difficult access primari outcom studi evalu pain palliat radiolog assess local tumor control | D017115;D000078703;D013125 | T191;T061 |
34,677,257 | cognit assess tool recommend geriatr oncolog guidelin rapid review cognit assess cornerston geriatr care cognit impair potenti signific impact multipl phase person cancer care experi accur identifi vulner challeng mani cancer care clinician thus use valid cognit assess tool recommend intern cancer guidelin older adult recommend geriatr assess ga includ evalu cognit clinician need familiar overal interpret common use cognit assess tool rapid review investig cognit assess tool frequent recommend geriatr oncolog guidelin bless orient memori concentr test bomc clock draw test cdt mini cog mini mental state examin mmse montreal cognit assess moca short portabl mental status questionnair spmsq detail apprais strength limit tool conduct focus practic aspect implement cognit assess tool real world clinic set final recommend choos assess tool addit consider beyond screen discuss | D060825;D009369 | T048;T191 |
34,677,256 | real world outcom patient advanc melanoma treat alberta canada time era base analysi immun checkpoint map kinas pathway inhibitor signific improv long term surviv patient melanoma limit real world data regimen effect retrospect analyz patient unresect metastat melanoma august juli treat immun checkpoint inhibitor map kinas pathway target therapi alberta canada overal surviv os compar use kaplan meier cox regress analys subgroup surviv outcom analyz first line treatment regim braf mutat status three treatment era defin base drug access prior august august novemb novemb juli across era improv median os month month month respect patient braf mutant melanoma improv median os treat immunotherapi first line oppos target therapi median os reach immunotherapi versus month target treatment patient braf wild type melanoma improv surviv ipilimumab nivolumab versus treat singl agent pd inhibitor median os reach month real world analysi confirm signific surviv improv subsequ introduct novel therapi advanc melanoma | D008545 | T191 |
34,677,255 | rethink clinic trial react program canadian led pragmat trial program strategi integr knowledg user trial design review patient health care provid hcp survey perform react program react team perform patient survey respond hcp survey respond address broad rang topic breast cancer manag time proport survey distribut paperregular mail fallen electron distribut norm patient survey median durat survey month iqr month median respons rate iqr hcp survey median survey durat month iqr month median respons rate avail iqr survey data far led systemat review peer review grant applic clinic trial knowledg user essenti compon clinic research react program integr survey standard step trial process covid pandem reduc face face interact patient clinic well continu import social media highlight need altern mean distribut respond survey | D000086382;D058873 | T047;T067 |
34,677,254 | combin exoscop endoscop techniqu craniofaci resect determin feasibl combin exoscop endoscop techniqu cee altern microscop craniofaci resect cfr retrospect studi conduct singl institut includ eight consecut patient head neck tumor underw cfr septemb juli transcrani approach microsurgeri perform use exoscop manner tradit microscop surgeri endoscop use blind spot exoscop exoscop provid imag suffici qualiti perform microsurgeri sphenoid sinus lumen blind spot exoscop anterior n anterolater cfr n medial aspect tempor bone blind spot exoscop tempor bone resect n blind spot visual endoscop facilit accur transect skull base advantag exoscop endoscop includ compact size ergonom surgic field access equal visual experi neurosurgeon head neck surgeon enabl simultan transcrani transfaci surgic procedur surgeri success without relev complic cee effect transcrani skull base surgeri especi cfr involv simultan surgic procedur | D004724;D019291 | T029;T060 |
34,677,253 | intraop radiotherapi balloon base electron brachytherapi system systemat review first bulgarian experi breast cancer patient background aim analyz current avail studi intraop radiotherapi iort choic treatment xoft axxent electron brachytherapi ebx system use singl dose irradi exclus radiotherapi approach time surgeri patient earli breast cancer ebc also compar result systemat review bulgarian experi method materi perform systemat review studi publish februari investig applic singl fraction gy radiat treatment deliv time lumpectomi ebc patient xoft axxent ebx system systemat search pubm scopus sciencedirect perform result report follow prisma guidelin criteria patient select iort addit need ebrt cosmet outcom recurr rate elig studi compar treatment result bulgarian patient result search result find elig studi publish outcom random trial report cosmet outcom studi defin excel observ recurr rate low still number patient addit refer postop extern breast radiotherapi ebrt amongst patient treat bulgaria cosmet outcom also evalu excel five refer ebrt within median follow month one local one distal recurr conclus current evid demonstr xoft axxent ebx system safe feasibl techniqu iort deliveri ebc patient random control trial conduct time point prove long term effect better patient select reimburs strategi propos extend applic techniqu bulgaria | D001918;D001943 | T191;T061 |
34,677,252 | psychosoci function predictor mental disord among prostat cancer survivor inform survivorship care program evid base knowledg recent research reveal prostat cancer pca survivor face silent epidem mental disord find surpris side effect high effect current treatment modal consid assess associ urinari function qualiti life indic mental disord among survivor pca cross section examin analyt sampl men histori pca resid maritim took survey assess social physic health relat qualiti life indic mental disord assess use kessler psycholog distress scale k predictor variabl includ emot function socialfamili spiritu well measur function assess cancer therapi prostat fact p urinari function measur intern prostat symptom score ipss multivari logist regress analysi evalu contribut predictor control age incom survivorship time month sinc diagnosi relationship status treatment modal mental disord identifi among pca survivor sampl high emot aor ci spiritu well aor ci protect factor mental disord men screen posit moder sever urinari tract symptom three time higher odd aor ci screen posit mental disord men activ surveil radic prostatectomi without ad treatment higher aor ci aor ci respect odd screen posit mental disord compar men receiv radiat treatment without hormon therapi pca diagnosi unmet emot spiritu need increas urinari problem form treatment eg activ surveil surgeri associ mental disord among pca survivor develop survivorship care program support system focus long term effect pca treatment consequ unmet psychosoci need patient survivorship journey critic need | D000073116;D001523;D011471 | T048;T191;T101;T201 |
34,677,251 | treatment regret mental physic health indic psychosoci well among prostat cancer survivor prostat cancer pca patient survivor high risk mental health ill examin contribut treatment regret mental physic health indic socialfamili emot function spiritu well pca survivor studi assess men histori pca resid maritim canada survey outcom socialfamili emot function spiritu well fact p facit sp predictor variabl includ urinari bowel sexual function ucla pci physic mental health sf treatment regret logist regress analys control age incom survivorship time poor socialfamili emot function spiritu well identifi among men sampl men report treatment regret higher odd poor socialfamili emot function well respect men low household incom time higher odd poor socialwel good mental health protect factor poor socialfamili emot function spiritu well better physic sexual health protect factor poor function well seek promot pca patient autonomi treatment decis recogn process vulner health care context warrant | D000073116;D062645;D011471 | T061;T191;T101;T201 |
34,677,250 | spinal manifest malign primari plb secondari bone lymphoma slb manifest malign lymphoma spine rare case report literatur due rariti gold standard manag patient suffer spinal lymphoma manifest method retrospect review data patient femal male malign lymphoma spine receiv intervent center march june neurolog impair pain diagnost andor surgic instabl criteria surgeri patient cohort otherwis ct guid biopsi conduct analysi patient cohort base karnofski perform status scale kpss locat lesion spinal level involv spinal instabl neoplast score sin surgic treatment histopatholog workup adjuv therapi overal surviv follow surgic procedur perform posterior stabil decompress nine patient decompress andor tumor debulk patient two stage procedur dorsal stabil vertebr bodi replac four patient decompress biopsi one patient two stage procedur kyphoplasti posterior stabil one patient posterior stabil without decompress one patient vertebroplasti cement augment posterior stabil one patient ct guid biopsi alon two patient twenti one patient lesion thorac spine patient lesion lumbar spine two patient lesion cervicothorac junction two patient lesion thoracolumbar junction one patient lesion lumbosacr junction one patient lesion sacrum diagnos histopatholog workup diffus larg b cell lymphoma case indol lymphoma case anaplast cell lymphoma one case cell lymphoma one case burkitt lymphoma one case median overal surviv month rang month pre postop kpss score iqr manifest malign lymphoma spine rare similar approach taken spine metastas surgic intervent case neurolog impair manifest potenti instabl indic follow chemoimmunotherapi radiotherapi | D008223;D013904 | T191;T023 |
34,677,249 | prognost factor influenc surviv treatment pattern analysi convent palliat radiotherapi patient bone metastas treatment indic bone metastas influenc patient prognosi singl fraction radiotherapi sfrt proven equal effect multipl fraction regimen mfrt continu underus | D001859;D018787 | T091;T191 |
34,677,248 | challeng return work breast cancer role famili situat canto cohort return work rtw breast cancer associ improv qualiti life link household characterist rtw remain larg unknown aim studi examin effect famili situat women rtw two year breast cancer use data french prospect cohort women diagnos stage iii primari breast cancer canto nct among women employ diagnosi year old assess associ household characterist live partner marit status number age econom depend children support partner rtw logist regress model adjust age household incom stage comorbid treatment side effect analyz stratifi age household incom perform assess associ household characterist rtw specif subgroup among patient includ women live partner return less work decreas work time rtw among women live partner marri associ decreas rtw among women age three children vs none associ lower rtw among women low household incom household characterist consid addit clinic inform identifi vulner women reduc social consequ cancer improv qualiti life | D001943;D062707 | T033;T191 |
34,677,247 | craft propos framework decentr clinic trial particip canada canada vast geographi central deliveri cancer care clinic trial creat barrier trial particip patient remot rural set develop implement framework enabl safe regulatori compliant trial particip local healthcar provid would benefit canadian patient clinician trial sponsor health care system address issu repres canada cancer clinic trial communiti met identifi key challeng develop recommend remot patient particip trial structur literatur review identifi remoterur trial deliveri model panel expert stakehold review model particip workshop assess health system readi identifi need process tool mechan develop recommend canadian framework decentr clinic trial conduct canadian remot access framework clinic trial craft repres risk base approach use site investig deleg respons given trial satellit health centr within hub spoke trial cluster framework includ specif recommend ensur research experi capac regulatori complianc patient safeti canada cancer care telemedicin system leverag enabl broader access clinic trial patient geograph remot cancer centr craft risk base framework base success model remot trial patient manag pilot implement phase canada | D017216 | T058 |
34,677,246 | prognost radiolog tool clinic stage ia pure solid lung cancer studi analyz prognost radiolog tool surgic outcom radiolog pure solid adenocarcinoma ad squamous cell carcinoma sq clinic stage ia retrospect investig patient underw surgic resect assess predict risk factor recurr patholog lymph node metastasi lnm statist differ recurr free surviv rfs cancer specif surviv css ad sq group p p respect whole cohort tumor size lung window mediastin set tumor disappear ratio use high resolut comput tomographi hrct prognost paramet p respect maxim standard uptak valu suvmax use positron emiss tomographi ct associ recurr p accord receiv oper characterist curv cut valu suvmax recurr p quantit continu variabl use radiolog tool associ lnm howev tumor diamet mediastin set mm suvmax could risk factor lnm pure solid ad sq equival rfs css suvmax use predict recurr tumor diamet mediastin set suvmax use predict patholog lnm | D019788;D008175 | T130;T191;T109 |
34,677,245 | express senesc apoptosi biomark synchron bilater breast cancer case report synchron bilater breast cancer sbbc provid special condit two independ breast tumor expos cancer pharmacotherapi within uniform pharmacokinet milieu senesc apoptosi establish respons therapi howev potenti variabl contribut overal outcom treatment yet determin | D001943;D009378 | T191 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.